The global Chronic Cough Market is projected to experience consistent revenue growth throughout the forecast period. Several key factors contribute to this growth, including the high prevalence of chronic lung infections, a robust pipeline portfolio, and the common occurrence of chronic cough as a symptom. Additionally, the market is driven by the vulnerability of individuals to both indoor and outdoor allergens, as well as advancements in treatment options.
Chronic cough is defined as a persistent cough that lasts for more than six to eight weeks. It has a significant negative impact on patients' quality of life, causing disruptions in sleep, discomfort, dizziness, and even rib fractures. Multiple factors contribute to the occurrence of chronic cough, including infections, asthma, and gastroesophageal reflux disease (GERD). The increasing incidence of chronic cough cases and the expansion of product development to address associated symptoms such as runny or stuffy nose, postnasal drip, headache, sore throat, hoarseness, shortness of breath, and wheezing, are expected to drive revenue growth in the chronic cough market. Furthermore, chronic cough can lead to postnasal drip, asthma, and gastroesophageal reflux disease.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/5484
Factors Supporting Revenue Growth of the Market:
- Increasing incidence of chronic cough: A study reported 439 incident cases of chronic cough with an overall incidence rate of 11.6 per 1,000 person-years during a mean follow-up of six years. Age and sex did not show significant differences in the incidence rate of chronic cough in the study population. However, obese patients had a higher incidence of chronic cough compared to non-obese patients, and current smokers had a higher prevalence than non-smokers. Additionally, men were more likely to experience chronic cough than women.
Factors Restraining Revenue Growth of the Market:
Despite the projected revenue growth, several factors may hinder the market's expansion. These include a lack of technical expertise or professionals with the required training, high treatment costs, and product recalls. For example, in June 2020, GSK Consumer Healthcare voluntarily recalled certain "Children's Robitussin Honey Cough and Chest Congestion DM" and "Children's Dimetapp Cold and Cough" products due to "incorrect dosage cups," as stated in the recall notice published on the U.S. Food and Drug Administration (FDA) website.
Opportunity in the Global Chronic Cough Market:
Opportunities in the chronic cough market arise from factors such as an increase in asthma and gastroesophageal reflux disease, as well as the development of novel diagnostic technologies. The presence of potential candidates and the demand for new drug development to treat chronic cough create lucrative opportunities for market players.
Geographic Market Scenario:
Largest Market Share: North America holds the largest market share during the forecast period due to the high prevalence of respiratory disorders and the presence of a sophisticated healthcare infrastructure, enabling efficient treatment for patients requiring cough suppressant medication. Additionally, Europe is considered a competitive market due to the presence of domestic and global significant companies in this sector, as well as an increasing focus on research and development.
Fastest Growing Region: The Asia Pacific region is expected to demonstrate steady revenue growth throughout the forecast period. Factors contributing to this growth include rising healthcare spending, an increasing prevalence of respiratory diseases, and the impact of a sedentary lifestyle on the occurrence of cough, which drives market revenue growth.
Key Market Trends and Innovation:
In terms of key market trends and innovation, in February 2022, Seoul National University Bundang Hospital reported that clinical studies for the effect of magnesium on remifentanil-induced cough are in phase 4, with an estimated completion date of December 2022. In February 2021, a recent study suggested that lidocaine throat spray could be a therapeutic option for persistent chronic cough, offering a potential treatment for Refractory Chronic Cough (RCC). This innovative approach, which involves converting lidocaine into a spray form, may attract key players in the market and create new opportunities.
Competitive Landscape:
Companies in the chronic cough market adopt both organic and inorganic strategies to enhance their market position. For instance, in January 2022, Merck announced FDA approval of Gefapixant, a non-narcotic, oral selective P2X3 receptor antagonist for the treatment of patients with Refractory Chronic Cough (RCC) or unexplained chronic cough (UCC).
To know more about the latest insights of the report, visit @ https://www.reportsanddata.com/request-latest-insight/5484
Major Companies in the Market Include:
The major companies operating in the chronic cough market are GSK plc, Teva Pharmaceuticals Industries, Mylan N.V., Sun Pharmaceuticals Industries Ltd, Cipla Limited, Aurobindo Pharma, Amneal Pharmaceuticals LLC, Novartis AG, Hikma Pharmaceuticals Plc, Apotex Inc., Micro Labs Ltd, AstraZeneca plc, Bayer AG, Glenmark Pharmaceuticals Ltd, and NeRRe Therapeutics.
Segmentation:
The market is segmented based on treatment outlook, route of administration outlook, distribution channel outlook, end-user outlook, and region outlook.
By Treatment Outlook:
- Antihistamines
- Corticosteroids
- Decongestants
- Combination Drugs
- Antibiotics
- Acid Blockers
- Other Drug Classes
By Route of Administration Outlook:
- Oral
- Parenteral
- Other
By Distribution Channel Outlook:
- Online Channel
- Offline Channel
By End User Outlook:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region Outlook:
- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., France, Italy, Spain, Sweden, BENELUX, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Rest of APAC)
- Latin America (Brazil, Rest of LATAM)
- Middle East Africa (Saudi Arabia, UAE, South Africa, Israel, Rest of MEA)
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/5484
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact:
John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs
